A new market study published by Global Industry Analysts (GIA), released its report titled, ``Healthcare Supply Chain Management—Global Market Trajectory & Analytics.’’ We present excerpts from the report
The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial
If approved it will bring a second source of MMR vaccine to the US market
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
Nearly 6,000 patients have been treated with the drug since 2017
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
A globally approved pen filled by mass technology provides a safer self- administration fertility solution
Deal signed with AOP Orphan for US commercial rights
A veteran in cell therapy and oncology commercialisation
Subscribe To Our Newsletter & Stay Updated
